KAHR and Cancer Focus Fund Announce First Patient to Receive Dose in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

A trial evaluating DSP107, a first-in-class fusion protein targeting CD47x41BB, in blood cancers is underway at MD Anderson and funded by an investment from the Cancer Focus Fund

Phase 1b the clinical trial is an open-label, dose-escalation trial of DSP107 as monotherapy and in combination with azacitidine or with azacitidine plus venetoclax in patients with AML and MDS

DSP107 is also being evaluated in a Phase 1/2 clinical trial as monotherapy and in combination with atezolizumab in patients with advanced solid tumors as part of a clinical collaboration with Roche

JERUSALEM and Houston, TX, February 17, 2022 /PRNewswire/ — KAHR, a clinical-stage oncology company developing novel dual-targeted fusion protein therapies, and Cancer Focus Fund, LP, a unique investment fund created in collaboration with The University of Texas The MD Anderson Cancer Center will provide funding and clinical expertise to advance promising cancer therapies, the first patient received a dose in a phase announced today 1b clinical trial of DSP107, KAHR’s CD47x41BB-targeting fusion protein, in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The clinical trial is funded by a previously announced investment from the Cancer Focus Fund.

“The initiation of our second clinical trial of DSP107 is another important milestone for KAHR, and we appreciate the support of the Cancer Focus Fund in making it possible,” said Yaron Pereg, Ph.D., President and CEO of KAHR. . “This trial in difficult blood cancers complements our ongoing Phase 1/2 clinical trial in patients with advanced solid tumors. The distinctive mechanism of action of DSP107 and the data observed in our preclinical studies and clinical trials at to date suggest that it may have the potential to achieve significant anti-tumor effects on all types of cancer.”

“KAHR’s dual-targeting fusion proteins exemplify the kind of novel cancer therapies we seek to support,” said Ross Barrett, founder and managing partner of the Cancer Focus Fund. “We are optimistic that DSP107 could be a prime example of how our partnership with MD Anderson and innovative drug developers has the potential to facilitate important cancer clinical trials, help advance important new therapies and, ultimately, to improve the lives of cancer patients, while rewarding our public and private funders.”

The open-label, two-part, dose-escalation study is being conducted at MD Anderson and led by Naval Daver, MD, associate professor of leukemia. It evaluates the safety, efficacy, pharmacokinetics and pharmacodynamics of DSP107 as monotherapy and in combination with azacitidine or with azacitidine plus venetoclax in patients with relapsed/refractory AML or in patients with MDS who have failed previous treatment regimens. The first part of the trial is a dose escalation study to explore the safety, efficacy, pharmacokinetic and pharmacodynamic profile of DSP107 when administered as monotherapy and in combination with azacitidine. In the second part of the trial, venetoclax will be added to the combined regimen.

Dr Pereg added: “We continue to make good progress in the ongoing Phase 1/2 trial of DSP107 as monotherapy and in combination with atezolizumab in patients with advanced solid tumors under our agreement. clinical collaboration with Roche. We have completed recruitment of the monotherapy dose escalation cohorts and are now treating patients with the combination of DSP107 and atezolizumab.

The results accumulated to date demonstrate a favorable preliminary safety profile, with no dose-limiting toxicity and no hematological or hepatotoxic toxicity. Importantly, data from tumor biopsies before and after treatment show increased infiltration of immune cells into the tumor with increased tumor necrosis. »

About DSP107

DSP107 is a dual-targeting fusion protein that binds both cancer cells and immune cells, connecting them for increased activation of the anti-tumor immune system, including weakening tumor defenses and activating innate anti-tumor immune responses and local adaptations. DSP107 binds and inhibits CD47, an immune checkpoint protein overexpressed in many types of cancer that allows the tumor to evade immune recognition and macrophage attack. Simultaneously, DSP107 binds to 4-1BB, a co-stimulatory receptor expressed on T cells that stimulates their activation. These activities result in targeted immune activation mediated by macrophages and T cells and tumor destruction. DSP107 is in a Phase 1/2 clinical trial for solid tumor and stage-stage cancers. 1b test for blood cancers.

About KAHR

KAHR is developing novel dual-targeting fusion protein therapies designed to simultaneously activate the innate and adaptive immune systems and localize this response to the tumor microenvironment. KAHR’s lead drug candidate, DSP107, is a CD47x4-1BB targeting compound. DSP107 is tested in a Phase 1b clinical trial in blood cancers and a Phase 1/2 clinical trial in advanced solid tumors. KAHR’s preclinical pipeline also includes DSP502, a fusion protein targeting TIGITxPD1, and DSP216, a fusion protein targeting HLA-GxCD47. For more information, visit kahrbio.com/.

About the Cancer Fight Fund

The Cancer Focus Fund LP is a unique investment fund created in collaboration with The University of Texas MD Anderson Cancer Center. The fund provides investment support to advance promising cancer therapies that are poised to be tested in humans, as well as the clinical trial expertise and infrastructure of MD Anderson and its strategic partners Ochsner Health System Precision Cancer Therapies Program New Orleans and LSU Feist Weiller Cancer Center Shreveport. The fund’s objective is to take advantage of this unique combination to provide investors with superior risk-adjusted returns. With fund partner at MD Anderson, the Cancer Focus Fund provides both capital and translational research expertise with the goal of accelerating the development of new cancer therapies that result in better patient outcomes while generating returns for investors.


the University of Texas The MD Anderson Cancer Center’s relationship with the Cancer Focus Fund, and all research conducted at MD Anderson related to the Cancer Focus Fund, has been identified as an Institutional Financial Conflict of Interest by the Institutional Conflict of Interest Committee. MD Anderson and are therefore managed under an institutional conflict of interest. Interest management and monitoring plan.


Chuck Padala
LifeSci Advisors
+1 917-741-7792

Tsipi Haitovsky
Global Media
[email protected]

Cancer Fund
Business :
Ross Barrett
Managing Partner
[email protected]

Barbara Lindheim
BLL partners for
Cancer Fund
+1 917 355-9234
[email protected]

MD Anderson
Clayton Bold
Public relations
MD Anderson
+1 713 792-9518
[email protected]


View original content: https://www.prnewswire.com/news-releases/kahr-and-cancer-focus-fund-announce-first-patient-dosed-in-phase-1b-clinical-trial-of-anti – cd47-product-candidate-dsp107-in-blood-cancer-301484721.html


Comments are closed.